Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. The company is headquartered in Princeton, New Jersey and currently employs 34,100 full-time employees.  The company is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Opdualag (nivolumab and relatlimab-rmbw), Breyanzi (lisocabtagene maraleucel), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), and Sotyktu (deucravacitinib). Its other growth products include Onureg, Inrebic, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension). Opdivo (nivolumab) is a fully human monoclonal antibody that binds to the PD-1 on T and NKT cells.

Bristol Myers Squibb Co. terlibat dalam penemuan, pengembangan, lisensi, manufaktur, pemasaran, distribusi, dan penjualan produk biopharmaceutical. Perusahaan ini berkantor pusat di Princeton, New Jersey dan saat ini mempekerjakan 34.100 karyawan penuh waktu. Perusahaan ini terlibat dalam penemuan, pengembangan, dan pengiriman obat transformasional untuk pasien yang menghadapi penyakit serius di bidang: onkologi, hematologi, imunologi, kardiovaskular, neurosciences, dan bidang lainnya. Portofolio pertumbuhannya mencakup Opdivo (nivolumab), Opdivo Qvantig (nivolumab dan hyaluronidase-nvhy), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Opdualag (nivolumab dan relatlimab-rmbw), Breyanzi (lisocabtagene maraleucel), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), dan Sotyktu (deucravacitinib). Produk pertumbuhan lainnya termasuk Onureg, Inrebic, dan Empliciti. Portofolio legasinya mencakup Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), dan Abraxane (partikel paclitaxel terikat albumin untuk suspensi injeksi). Opdivo (nivolumab) adalah antibodi monoklonal manusia sepenuhnya yang mengikat PD-1 pada sel T dan NKT.

Bristol-Myers Squibb

NVIDIA

Apple

Google

Microsoft

Amazon

Broadcom

Meta Platforms

Taiwan Semiconductor

Tesla

Berkshire Hathaway

Walmart

Eli Lilly

JPMorgan

Visa

Oracle

Exxon Mobil

MasterCard

Johnson & Johnson

Palantir

SPDR S&P500 ETF

ASML

Netflix

Bank of America

AbbVie

Costco

Alibaba

Home Depot

Procter & Gamble

Cisco

Vanguard Total Stock Market ETF

Chevron

Coca-Cola

General Electric

UnitedHealth Group

Wells Fargo

Caterpillar

Morgan Stanley

AstraZeneca

Micron Technology

Goldman Sachs

American Express

Toyota

Novartis

Salesforce

Merck

T-Mobile

Philip Morris

Raytheon Technologies

Royal Bank of Canada

McDonald's

Abbott

Applied Materials

Novo Nordisk

Shopify

Shell

Intuitive Surgical

Invesco QQQ Trust

Citigroup

Lam Research

PepsiCo

Intel

Uber

Disney

QUALCOMM

Intuit

Linde PLC

Blackstone

AT&T

ServiceNow

Amgen

Verizon

NextEra Energy

Charles Schwab

Sony

Booking Holdings

BlackRock

Accenture

Texas Instruments

Danaher

Arista Networks

Banco Santander

Boeing

S&P Global

Toronto-Dominion Bank

Gilead Sciences

Pfizer

Capital One

Adobe

Unilever

Boston Scientific

TotalEnergies

Union Pacific

Lowe's

Analog Devices

Bristol-Myers Squibb Stock

About Bristol-Myers Squibb

Key Statistics